Bright Peak Therapeutics Inc. closed a $107 million series B round to progress a pipeline of engineered cytokines, which are produced using a chemical synthesis method instead of classical recombinant protein production approaches.
Flagship Pioneering Inc., the serial biotech-founding investor that created RNA trailblazer Moderna Inc., is putting its money behind Senda Biosciences Inc. and a technology that aims create medicines by changing the way the body interacts with organisms such as plants and microbes. Senda has just announced the closing of a $98 million series B funding round, after completing a $55 million extension that brings total funding raised so far to $143 million.
Medtrace Pharma A/S raised $30 million in a series B round to ramp its platform for production, infusion and analysis of 15O-water in medical imaging. Swiss-based Swisscanto Invest, along with fund managers ATP and Bankinvest group from Denmark, are the lead investors. “We can now ramp our European and U.S. expansions plans in myocardial perfusion imaging and in other indications in need of perfusion data,” Martin Stenfeldt, CEO and co-founder of Medtrace, told BioWorld.
Taking its mission as looking at how cells function as opposed to looking at them anatomically, Kojin Therapeutics Inc. is launching with a $60 million series A to accelerate its ferroptosis-, or iron-dependent cell death-, based discovery platform for tackling hard-to-treat diseases, including drug-resistant cancers.
For the second time, the biopharma industry’s largest event will be held virtually as BIO Digital 2021, with pandemic preparedness and infectious diseases a running theme throughout many of the scheduled sessions.
The Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF) has raised more than half of its proposed ¥2 billion (US$313 million) round. “The second fund, GIBF2, will focus on Israeli and European biotechnology companies, which are developing innovative drugs and are in phase II to III clinical trials,” Avner Lushi, the CEO and co-founder of the GIBF, told BioWorld. The Chinese RMB fund is managed by The Guangzhou Elim Biotech Industry Venture Capital Management Company, which is controlled by a group of prominent Israeli professionals.
Although 2020 is the highest money-making year on record for the biopharma industry, a direct comparison of the first five months indicates that the amount raised so far in 2021 is 22% ahead of last year, while the number of financings climbed 26%.
RSS
